58.07

2.87% 1.62

After Hours: 58.00 -0.07 -0.12%

Keros Therapeutics Inc (KROS)

Overview News Price History Option Chain Financials Why KROS Down? Discussions Forecast

Keros Therapeutics Inc stock is traded at $58.07, with a volume of 343.82K. It is up +2.87% in the last 24 hours and up +28.05% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Previous Close:

$56.45

Open:

$56.38

24h Volume:

343.82K

Relative Volume:

1.00

Market Cap:

$2.18B

Revenue:

Net Income/Loss:

$-168.05M

P/E Ratio:

-12.79

EPS:

-4.54

Net Cash Flow:

$-146.15M

1W Performance:

+6.47%

1M Performance:

+28.05%

6M Performance:

-12.28%

1Y Performance:

+82.15%

1-Day Range:

$55.53

$58.40

1-Week Range:

$53.65

$59.06

52-Week Range:

$27.02

$73.00

Keros Therapeutics Inc Stock (KROS) Company Profile

Name

Keros Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

617-314-6297

Address

1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA

Employee

149

Twitter

Next Earnings Date

2024-08-05

Latest SEC Filings

KROS's Discussions on Twitter

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jul-31-23	Initiated	Wedbush	Outperform
Jul-26-23	Initiated	BofA Securities	Buy
Feb-14-23	Initiated	Cowen	Outperform
Oct-18-22	Initiated	Truist	Buy
Jul-26-22	Initiated	BTIG Research	Buy
Dec-08-20	Reiterated	H.C. Wainwright	Buy
May-04-20	Initiated	H.C. Wainwright	Buy
May-04-20	Initiated	Jefferies	Buy
May-04-20	Initiated	Piper Sandler	Overweight
May-04-20	Initiated	SVB Leerink	Outperform

View All

Keros Therapeutics Inc Stock (KROS) Latest News

04:51 AM

Keros Therapeutics completes enrollment for TROPOS trial - Investing.com

04:51 AM

08:20 AM

Point72 Asset Management L.P. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

08:20 AM

Sep 29, 2024

Wells Fargo Initiates Coverage of Keros Therapeutics (KROS) with Overweight Recommendation - MSN

Sep 29, 2024

Sep 28, 2024

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Blue Owl Capital Holdings LP - MarketBeat

Sep 28, 2024

Fred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 28, 2024

Sep 27, 2024

Iron Deficiency Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Shield Therapeutics, Zeria Pharma, Keros Therapeutics - The Globe and Mail

Sep 27, 2024

Fred Alger Management LLC Has $2.24 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Sep 27, 2024

Sep 26, 2024

Darwin Global Management Ltd. Boosts Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 26, 2024

Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail

Sep 26, 2024

17,540 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Purchased by Point72 DIFC Ltd - MarketBeat

Sep 26, 2024

Sep 24, 2024